Catalyst Wire Dossier Catalyst Wire Dossier

AKR-501

· Eisai Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for AKR-501, covering 2018-01-04 to 2018-03-16. Get the full timeline:

Most recent: Clinical Trial Update: Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003 [Phase 2]

See pricing